AbbVie, Inc. (ABBV)
255.91
-2.24
(-0.87%)
USD |
NYSE |
Aug 28, 15:30
AbbVie Cash from Operations (Quarterly) : 3.436B for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.436B |
| March 31, 2026 | 3.829B |
| December 31, 2025 | 5.218B |
| September 30, 2025 | 7.024B |
| June 30, 2025 | 5.153B |
| March 31, 2025 | 1.635B |
| December 31, 2024 | 7.048B |
| September 30, 2024 | 5.447B |
| June 30, 2024 | 2.271B |
| March 31, 2024 | 4.04B |
| December 31, 2023 | 4.715B |
| September 30, 2023 | 7.574B |
| June 30, 2023 | 6.319B |
| March 31, 2023 | 4.193B |
| December 31, 2022 | 7.428B |
| September 30, 2022 | 7.602B |
| June 30, 2022 | 5.005B |
| March 31, 2022 | 4.908B |
| December 31, 2021 | 5.075B |
| September 30, 2021 | 7.935B |
| June 30, 2021 | 4.89B |
| March 31, 2021 | 4.877B |
| December 31, 2020 | 4.854B |
| September 30, 2020 | 5.83B |
| June 30, 2020 | 3.089B |
| Date | Value |
|---|---|
| March 31, 2020 | 3.815B |
| December 31, 2019 | 3.275B |
| September 30, 2019 | 4.726B |
| June 30, 2019 | 2.306B |
| March 31, 2019 | 3.017B |
| December 31, 2018 | 3.392B |
| September 30, 2018 | 4.524B |
| June 30, 2018 | 2.866B |
| March 31, 2018 | 2.645B |
| December 31, 2017 | 2.584B |
| September 30, 2017 | 3.271B |
| June 30, 2017 | 2.003B |
| March 31, 2017 | 2.102B |
| December 31, 2016 | 1.541B |
| September 30, 2016 | 1.454B |
| June 30, 2016 | 1.918B |
| March 31, 2016 | 2.128B |
| December 31, 2015 | 1.963B |
| September 30, 2015 | 2.155B |
| June 30, 2015 | 1.832B |
| March 31, 2015 | 1.585B |
| December 31, 2014 | -578.00M |
| September 30, 2014 | 1.786B |
| June 30, 2014 | 1.717B |
| March 31, 2014 | 624.00M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Biogen, Inc. | 448.90M |
| Gilead Sciences, Inc. | 3.573B |
| Regeneron Pharmaceuticals, Inc. | 813.00M |
| Amgen, Inc. | 4.002B |
| REGENXBIO, Inc. | -62.24M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -1.197B |
| Cash from Financing (Quarterly) | -5.054B |
| Free Cash Flow | 18.21B |
| Free Cash Flow Per Share (Quarterly) | 1.758 |
| Free Cash Flow to Equity (Quarterly) | 5.15B |
| Free Cash Flow to Firm (Quarterly) | 3.780B |
| Free Cash Flow Yield | 4.01% |